FOXO4-DRI.
FOXO4-DRI is a synthetic senolytic peptide derived from the transcription factor FOXO4 (Forkhead box O4).
FOXO4-DRI is a synthetic senolytic peptide derived from the transcription factor FOXO4 (Forkhead box O4). FOXO4-DRI is research / preclinical, and PepCue grades its published evidence F tier (15/100). This is a research reference, not medical or dosing advice.
What it is
FOXO4-DRI is a synthetic senolytic peptide derived from the transcription factor FOXO4 (Forkhead box O4). It is built as a D-retro-inverso (DRI) isoform of FOXO4's p53-interacting region, composed of D-amino acids in reversed sequence, a design that mimics the natural peptide's binding surface while resisting protease degradation. It was first reported by Baar and colleagues in 2017 as a proof-of-concept tool for selectively eliminating senescent ("zombie") cells.
How it works
In senescent cells, FOXO4 protein accumulates and binds the tumor-suppressor p53, sequestering it in the nucleus and preventing p53 from triggering apoptosis, which keeps damaged senescent cells alive. FOXO4-DRI acts as a competitive antagonist that disrupts the FOXO4–p53 interaction, freeing p53 to translocate and activate intrinsic apoptotic signaling (reported downstream involvement of BAX and caspase-3). Because non-senescent cells do not depend on this FOXO4–p53 interaction for survival, the peptide is proposed to kill senescent cells preferentially. A 2025 Nature Communications structural study identified the intrinsically disordered p53 transactivation domain as the binding target of both FOXO4 and FOXO4-DRI, refining the molecular picture.
Mechanism pathways
Targeting senescent cells, telomere maintenance, and NAD+ availability.
Cellular senescence is a state in which a damaged cell permanently stops dividing but does not die. Senescent cells accumulate with age and secrete a mix of inflammatory cytokines, proteases, and growth factors collectively called the senescence-associated secretory phenotype, which is thought to drive chronic low-grade inflammation in surrounding tissue. Clearing these cells in animal models has been associated with improvements in several age-related measures, which is the entire premise behind senolytic compounds. One compound here exploits a specific vulnerability. In senescent cells the transcription factor FOXO4 accumulates and binds the tumour suppressor p53, holding it in the nucleus and preventing it from triggering apoptosis. That interaction is what keeps a damaged cell alive when it should have died. A retro-inverso peptide designed to disrupt the FOXO4 and p53 interface frees p53 to initiate intrinsic apoptotic signalling. Because healthy cells do not depend on this interaction for survival, the effect is proposed to be selective for senescent cells. A second approach targets telomere maintenance. Telomeres shorten with each cell division until a cell reaches its replicative limit, and telomerase is the enzyme that can extend them. A short peptide in this group has been reported in cultured human cells to induce telomerase expression and extend the number of divisions past that limit, with a secondary proposed action on pineal function and melatonin output. A third targets NAD+ availability by inhibiting the enzyme that methylates nicotinamide and diverts it away from NAD+ salvage. NAD+ is a substrate for sirtuins and a central currency of cellular energy metabolism, and its decline with age is a well-described observation. Honesty about this pathway is essential. Senescence biology is real and actively researched, and the molecular interactions described above have been characterised in cells and rodents. What is missing is human evidence. There are no controlled clinical trials demonstrating that any of these compounds slow ageing, extend healthy lifespan, or improve any clinical outcome in people. Deliberately inducing apoptosis or manipulating telomerase activity also carries theoretical risks that have not been characterised in humans, since telomerase reactivation is a feature of many cancers. None of these compounds is approved anywhere, and all are sold as unregulated research material.
The evidence
The foundational evidence is preclinical: Baar et al. (Cell, 2017) showed in naturally aged mice that FOXO4-DRI reduced markers of senescence and improved fitness, fur density, and renal function, and counteracted doxorubicin chemotoxicity. Subsequent independent work extended in vitro and animal findings: for example, selective clearance of senescent cells from in-vitro-expanded human chondrocytes (Huang et al., Frontiers in Bioengineering and Biotechnology, 2021), and rodent studies in vascular endothelium, Leydig cells, and keloid fibroblasts. Critically, there are no completed or registered human clinical trials of FOXO4-DRI; all efficacy data come from cell culture and mouse models. Claims of anti-aging benefit in humans are therefore unproven and rest entirely on preclinical extrapolation.
The evidence, in brief
A synthetic D-retro-inverso senolytic peptide that disrupts the FOXO4–p53 interaction to trigger apoptosis in senescent cells. In the landmark Baar study it improved healthspan markers in aged and progeroid mice. Evidence is entirely preclinical, with no human trials.
- Baar MP et al.: Rejuvenation by Therapeutic Elimination of Senescent CellsCell, 2017 (PMID 28340347)
Evidence maturity
An evidence-only reading: approval status, human vs preclinical data, mechanism and safety. Popularity never raises it. Research file #020
Little indexed evidence or largely speculative.
A plausible biological rationale, but little data behind it.
Claim receipts
Popular claims about FOXO4-DRI, checked against the state of the evidence. The verdict describes evidence maturity, never an invented study result.
Selective clearance has been shown in cell culture and in aged mice, with no human study to confirm it.
Improvements in fitness, fur density and renal markers are mouse findings, and anti-aging benefit in people rests entirely on preclinical extrapolation.
There are no completed or registered human clinical trials of the peptide.
The mechanism releases p53 to drive apoptosis, and off-target activity plus the consequences of broad senescent-cell clearance are uncharacterized in humans.
Safety profile
Human safety data for FOXO4-DRI do not exist: it has not undergone formal clinical toxicology or trials, so its safety profile in people is unknown. Mechanistically, releasing p53 to drive apoptosis is a double-edged process: off-target or excessive activity could harm healthy proliferating tissues, and the consequences of broad senescent-cell clearance (e.g., effects on wound healing, immune function, or tissue repair) are not characterized in humans. Material sold online is research-use-only and not manufactured to pharmaceutical standards, raising additional concerns about purity, sterility, and contamination. No conclusions about long-term safety can be drawn from the available animal data.
Compound notes
- FOXO4-DRI is a D-retro-inverso peptide designed to disrupt the FOXO4–p53 interaction.
- It is a senolytic research tool: it aims to selectively trigger death of senescent (aged) cells, studied in mice.
- Not FDA-approved; highly experimental, mouse-stage research.
- No established human safety or efficacy.
Regulatory status
FOXO4-DRI is an investigational, research-use-only compound. It is not approved by the FDA (or any major regulator) for any indication, is not a marketed drug, and has no DailyMed monograph; it is sold only as a laboratory research chemical.
Sold research-use-only; human evidence is limited or preclinical.
By the numbers
- 01Class: senolytic peptide; a D-retro-inverso (D-amino-acid, reversed-sequence) analog of a FOXO4 segment, engineered for protease resistance
- 02First described by Baar et al. in Cell (2017) as a tool to selectively clear senescent cells
- 03Acts by disrupting the FOXO4–p53 protein interaction, freeing p53 to trigger apoptosis in senescent cells
- 04All efficacy evidence is preclinical (cell culture and mouse models); no human clinical trials have been completed or registered
- 05A 2025 Nature Communications study mapped its target to the disordered p53 transactivation domain
- 06Not FDA-approved; sold only as a research-use-only chemical with no established human safety profile
FOXO4-DRI: research formats
Choose the format you are researching to see route-specific notes.
Senolytic research peptide; IP injection used in mouse studies, SC in human research contexts.
FOXO4-DRI is a senolytic peptide studied for selective clearance of senescent cells. Animal studies used intraperitoneal (IP) injection; human research contexts use subcutaneous. Sold as a 10 mg vial.
Sources
Every factual claim above resolves to a real, published source.
- Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and AgingCell, 2017, Vol. 169; Baar MP et al.; PMID 28340339
- Senolytic Peptide FOXO4-DRI Selectively Removes Senescent Cells From in vitro Expanded Human ChondrocytesFrontiers in Bioengineering and Biotechnology, 2021; Huang Y et al.; PMID 33996787
- The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4-DRINature Communications, 2025; Bourgeois B et al.; PMID 40593617
- FOXO4-DRI: PubMed search of the primary literaturePubMed (NCBI) literature search, all peer-reviewed reports
Cite this page
PepCue. “FOXO4-DRI: the evidence.” PepCue, reviewed June 1, 2026. https://www.pepcue.app/p/foxo4-dri.
Log your doses, run the vial math, and keep a provider-ready record in PepCue.